US brand-name drug prices average more than four times those abroad

Americans pay more for prescription drugs than people in any other wealthy country, and the gap is largest for exactly the drugs that dominate the headlines. A RAND Corporation analysis of 2022 prices found that across all drugs, US prices were 2.78 times those in 33 other high-income countries — and for brand-name drugs specifically, US prices averaged 4.22 times the prices in those comparison nations [s1]. The reason is not that Americans consume more medicine. It is that the US, almost alone among rich countries, has no authority that sets or caps the price a new drug launches at.

What the comparison actually measured

RAND compared manufacturer-level prices — the prices before the rebates and discounts that flow between drug companies, insurers and middlemen — for the US against 33 other high-income countries, using 2022 volume and price data [s1]. On that basis the US accounted for 62% of total drug spending across the countries studied while making up just 24% of the volume of drugs sold [s1]. In other words, the same pills bought in similar quantities cost far more on the US side of the ledger.

The multiples are not uniform. Across the 33 comparison countries, US prices ranged from 1.72 times those in Mexico to 10.28 times those in Turkey [s1]. And there is one category that runs the other way: unbranded generic drugs, which make up the large majority of US prescriptions by volume, were priced at about 67% — 0.67 times — the average in the comparison countries — meaning American generics are actually cheaper than the international average [s1]. The entire pricing problem, in the RAND data, sits with brand-name drugs still under patent.

Why the launch price is the whole story

In most wealthy countries, when a manufacturer wants to sell a new drug, a government body negotiates or regulates the price it can charge, often benchmarking it against the drug's added benefit or against prices elsewhere. The US has had no equivalent. Manufacturers set a list price when a drug launches, and for decades the largest single purchaser — Medicare — was explicitly barred by statute from negotiating it.

That is what changed, narrowly, in 2022. In describing its new program, the Centers for Medicare & Medicaid Services wrote that "for the first time, the law provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition" [s2]. The phrasing is worth reading closely. The negotiation authority reaches only a small number of the highest-spending drugs, only after they have been on the market for years, and only for the Medicare program — not for the commercial insurance that covers most working-age Americans. It does nothing about the price a drug launches at, which remains whatever the manufacturer decides.

What a patent buys, and what it does not

The high prices RAND measured are concentrated in drugs protected from competition. A brand-name drug's patents and regulatory exclusivities give its maker a window — often more than a decade — during which no generic or biosimilar copy is allowed on the market. During that window there is no competitor to undercut the price, and in the US, no regulator to set a ceiling. That combination is why the same molecule can cost several times more here than in a country that regulates the launch price.

When that protection lapses and competitors enter, US prices for that molecule tend to fall hard and fast — which is precisely why the US has among the cheapest generics in the world even as it has the most expensive branded drugs [s1]. The system does eventually produce low prices; it just does so only once patents expire, and only for drugs that face competition. Roughly nine in ten US prescriptions are already filled with those low-cost generics. The spending is concentrated in the branded minority that RAND's 4.22-times figure describes.

What the evidence does not settle

The RAND study is a price comparison, not a verdict on causes or consequences. It does not measure whether higher US prices fund more of the world's drug research — a claim the industry makes and economists dispute — nor whether lower prices abroad would be sustainable if every country paid them. It also compares list-type manufacturer prices; the net prices actually paid in the US after confidential rebates are lower than list, though by how much varies enormously by drug and is not public for most products.

What the data does establish is narrow and solid: measured on a consistent basis, US prices for brand-name drugs are several times higher than in comparably wealthy countries, the gap is a pricing gap rather than a usage gap, and it is confined to drugs that still hold their patent protection. The US pays the most in the world for new medicines and among the least for old ones, and the dividing line between the two is competition.